Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
NCT04980027
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
228
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
Insulin glargine (U300)
Sponsor
Sanofi